Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
CanSino Biologics to Start China Trial of Inhaled COVID-19 Vaccine
Tianjin CanSino Biologics (HK: 6185; SHA: 688185) will start a clinical trial of an inhaled COVID-19 vaccine in
The company's Ad5-nCoV vaccine, which is delivered by an adenovirus Type 5 vector, is already approved for
In part, CanSino developed the vaccine based on work it had done previously on an inhaled tuberculosis vaccine along with its approved inoculated COVID vaccine.
"We think [inhaled] immunization is very effective for airborne diseases,” Dr. Yu said in an interview on CNBC at
Another
See our other articles on CanSino.
Disclosure: ChinaBio has a relationship to CanSino.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China